Literature DB >> 32791115

Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.

Sonja Lang1, Bernd Schnabl2.   

Abstract

The liver communicates with the intestine via the portal vein, biliary system, and mediators in the circulation. Microbes in the intestine maintain liver homeostasis but can also serve as a source of pathogens and molecules that contribute to fatty liver diseases. We review changes in the gut microbiota that can promote development or progression of alcohol-associated and non-alcoholic fatty liver disease-the most common chronic liver diseases in Western countries. We discuss how microbes and their products contribute to liver disease pathogenesis, putative microbial biomarkers of disease, and potential treatment approaches based on manipulation of the gut microbiota. Increasing our understanding of interactions between the intestinal microbiome and liver might help us identify patients with specific disease subtypes and select specific microbiota-based therapies. Published by Elsevier Inc.

Entities:  

Keywords:  ALD; NAFLD; NASH; alcohol use disorder; alcohol-associated liver disease; alcoholic hepatitis; metagenomics; microbiome; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis

Mesh:

Year:  2020        PMID: 32791115      PMCID: PMC7467841          DOI: 10.1016/j.chom.2020.07.007

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  81 in total

1.  Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.

Authors:  Na Jiao; Susan S Baker; Adrian Chapa-Rodriguez; Wensheng Liu; Colleen A Nugent; Maria Tsompana; Lucy Mastrandrea; Michael J Buck; Robert D Baker; Robert J Genco; Ruixin Zhu; Lixin Zhu
Journal:  Gut       Date:  2017-08-03       Impact factor: 23.059

2.  Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.

Authors:  Katharina Brandl; Phillipp Hartmann; Lily J Jih; Donald P Pizzo; Josepmaria Argemi; Meritxell Ventura-Cots; Sally Coulter; Christopher Liddle; Lei Ling; Stephen J Rossi; Alex M DePaoli; Rohit Loomba; Wajahat Z Mehal; Derrick E Fouts; Michael R Lucey; Francisco Bosques-Padilla; Philippe Mathurin; Alexander Louvet; Guadalupe Garcia-Tsao; Elizabeth C Verna; Juan G Abraldes; Robert S Brown; Victor Vargas; Jose Altamirano; Juan Caballería; Debbie Shawcross; Peter Stärkel; Samuel B Ho; Ramon Bataller; Bernd Schnabl
Journal:  J Hepatol       Date:  2018-04-12       Impact factor: 25.083

3.  Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.

Authors:  Magdalena Mazagova; Lirui Wang; Andrew T Anfora; Max Wissmueller; Scott A Lesley; Yukiko Miyamoto; Lars Eckmann; Suraj Dhungana; Wimal Pathmasiri; Susan Sumner; Caroline Westwater; David A Brenner; Bernd Schnabl
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

4.  Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity.

Authors:  Ekaterina Smirnova; Puneet Puri; Mark D Muthiah; Kalyani Daitya; Robert Brown; Naga Chalasani; Suthat Liangpunsakul; Vijay H Shah; Kayla Gelow; Mohammed S Siddiqui; Sherry Boyett; Faridoddin Mirshahi; Masoumeh Sikaroodi; Patrick Gillevet; Arun J Sanyal
Journal:  Hepatology       Date:  2020-07       Impact factor: 17.425

5.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

6.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

7.  Tributyrin supplementation protects mice from acute ethanol-induced gut injury.

Authors:  Gail A Cresci; Katelyn Bush; Laura E Nagy
Journal:  Alcohol Clin Exp Res       Date:  2014-05-30       Impact factor: 3.455

8.  Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis.

Authors:  Sonja Lang; Münevver Demir; Yi Duan; Anna Martin; Bernd Schnabl
Journal:  Liver Int       Date:  2020-01-23       Impact factor: 5.828

9.  A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research.

Authors:  M Poyet; M Groussin; S M Gibbons; J Avila-Pacheco; X Jiang; S M Kearney; A R Perrotta; B Berdy; S Zhao; T D Lieberman; P K Swanson; M Smith; S Roesemann; J E Alexander; S A Rich; J Livny; H Vlamakis; C Clish; K Bullock; A Deik; J Scott; K A Pierce; R J Xavier; E J Alm
Journal:  Nat Med       Date:  2019-09-02       Impact factor: 53.440

10.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

View more
  33 in total

Review 1.  Host-microbial interactions in metabolic diseases: from diet to immunity.

Authors:  Ju-Hyung Lee; Joo-Hong Park
Journal:  J Microbiol       Date:  2022-05-05       Impact factor: 3.422

2.  The fecal mycobiome in non-alcoholic fatty liver disease.

Authors:  Münevver Demir; Sonja Lang; Phillipp Hartmann; Yi Duan; Anna Martin; Yukiko Miyamoto; Marina Bondareva; Xinlian Zhang; Yanhan Wang; Philipp Kasper; Corinna Bang; Christoph Roderburg; Frank Tacke; Hans-Michael Steffen; Tobias Goeser; Andrey Kruglov; Lars Eckmann; Peter Stärkel; Derrick E Fouts; Bernd Schnabl
Journal:  J Hepatol       Date:  2021-12-10       Impact factor: 25.083

3.  Controversies surrounding peripheral cannabinoid receptor 1 in fatty liver disease.

Authors:  Beste Mutlu; Pere Puigserver
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

Review 4.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

Review 5.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

6.  Intestinal Microbiota Participates in the Protective Effect of HO-1/BMMSCs on Liver Transplantation With Steatotic Liver Grafts in Rats.

Authors:  Mengshu Yuan; Ling Lin; Huan Cao; Weiping Zheng; Longlong Wu; Huaiwen Zuo; Xiaorong Tian; Hongli Song
Journal:  Front Microbiol       Date:  2022-06-10       Impact factor: 6.064

Review 7.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

Review 8.  Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies.

Authors:  Youngmin A Lee; Scott L Friedman
Journal:  J Intern Med       Date:  2021-09-26       Impact factor: 8.989

9.  Targeting pathobionts for the treatment of alcohol-associated liver disease.

Authors:  Sonja Lang; Münevver Demir; Bernd Schnabl
Journal:  Liver Int       Date:  2020-11-17       Impact factor: 5.828

10.  A surgical method for continuous intraportal infusion of gut microbial metabolites in mice.

Authors:  Danny Orabi; Lucas J Osborn; Kevin Fung; William Massey; Anthony J Horak; Federico Aucejo; Ibrahim Choucair; Beckey DeLucia; Zeneng Wang; Jan Claesen; J Mark Brown
Journal:  JCI Insight       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.